Therapy (IMRT), and conventional tangential fields techniques were compared. For each treatment technique, skin doses were measured using paired thermoluminescent dosimeters placed on the patient's skin: (i) directly above the balloon catheter during MammoSite ® HDR brachytherapy treatments and (ii) 4 cm inside the treatment borders during the IMRT and conventional breast treatments. The mean dose measured was about 58% of the prescription dose for the patients treated using the MammoSite ® technique. On the other hand, for patients treated with IMRT and tangential fields, the mean dose was found to be about 69% and 71% of the corresponding prescription dose. This study suggests that in breast cancer radiation treatments the MammoSite ® HDR technique reduces skin doses compared to IMRT and tangential field techniques.
Introduction
Breast carcinoma is one of the most common neoplasms among women, and in the United States alone over 211,000 such cases are diagnosed annually (1). Breast conservation therapy (BCT) is an alternative to mastectomy for patients with stage I and II breast cancer because of equivalent local control (2) (3) (4) (5) (6) . Although BCT has become an accepted alternative for early stage breast cancer patients, a number of studies showed that only 10-70% of patients qualifying for BCT actually receive it (7-10). In breast conservation therapy, the entire breast is usually irradiated with external beam radiation therapy (EBRT) utilizing 2D, 3D, or IMRT planning and delivery techniques. The prescription dose is typically 50.0 Gy plus a tumor bed boost, delivered in 5-7 weeks in daily treatment. Recently, there is a renewed interest in short-course partial breast irradiation for early stage breast cancers that meet stringent clinical and pathological criteria (11, 12) . One of the approaches is to use high dose rate (HDR) brachytherapy with MammoSite ® applicator. This type of treatment typically requires 5-7 days (13, 14) .
The use of intensity-modulated radiation therapy (IMRT) in breast irradiation treatment offers the potential of improved dose homogeneity, reduced lung, heart, and contralateral breast doses. These dosimetric improvements may lead to better cosmetic results, lowered cardiac and pulmonary complications, and reduced risk of contralateral breast cancer. Similarly, the partial breast irradiation using HDR brachytherapy may also reduce lung, heart, contralateral breast, and skin doses. Reduction in skin dose may also lead to improvement of cosmetic results.
Several studies have indicated better cosmetic results for patients treated with MammoSite ® HDR technique (15) (16) (17) (18) (19) (20) . The purpose of this work was to measure the skin doses during partial breast irradiation using balloon-catheter based HDR brachytherapy and during the breast treatments using IMRT and the conventional radiation techniques, hypothesizing that a correlation can be established between the improved cosmetic results and the reduction in skin dose.
Materials and Methods
Between June 2002 and January 2004 at the University of Pittsburgh Cancer Institute, 39 patients with early stage breast cancer underwent lumpectomy followed by high-dose rate brachytherapy using the MammoSite ® applicator (Proxima Therapeutics, Inc., Alpharetta, GA). The study was approved by the Institutional Review Board and all patients signed informed consent to participate in this study. For each patient, a non-contrast enhanced CT scan in the treatment position was first acquired forty-eight hours after the MammoSite ® placement. It was decided to wait for forty-eight hours to allow for absorption of small air pockets around the implant. This scan was reviewed by a radiation oncologist and a medical physicist to ensure that the MammoSite ® balloon conformed to the cavity and was at least 5 mm from skin surface and chest wall. Oblique films were taken in the catheter's lumen plane to locate the geometric center of the balloon. Orthogonal films or CT scans approved by the physician were used for treatment planning. Figure 1 shows an example of dose points identified for calculating the dose to skin, lung, ribs, and aortic arch. Following the recommendations of RTOG 95-17 protocol (21) , a dose of 3.4 Gy per fraction was prescribed at a distance of 1 cm from the balloon surface. Patients were treated BID with a minimum of six hours apart to a total dose of 34.0 Gy. A Nucletron ® V2 afterloader [Nucletron, The Netherlands] was used with the MammoSite ® applicator for treatment and a single source dwell position, at the geometric center of the balloon, was used for treatment planning. CT scout images or an anterior film was taken using a simulator prior to each treatment to verify the volume of the balloon. An example of breast plan with isodoses using the MammoSite ® HDR is shown in Figure 2 .
Between March 2003 and January 2004, a second group of sixty-five patients underwent primary breast irradiation using external beam radiation therapy following breast-conserving surgery at the University of Pittsburgh Cancer Institute. Photon beams of 6, 10, or mixed 6/18 MV were used for these treatments. Of the sixty-five patients, fifty-two were treated with tangential field IMRT technique and the other thirteen were treated using conventional tangential fields with wedg-es. 3D dose calculations were performed for the conventional technique. All patients treated with IMRT technique had a treatment planning CT scan at which time the primary breast was outlined with a radiopaque wire. The tangential field borders that allowed 2 cm margin beyond the palpable breast tissue were also marked with a radiopaque wire. The primary breast, ipsilateral lung, and heart (for the left breast cancer patients) were contoured on the axial CT slices. Based on these volumes and specified dose constraints, inverse treatment planning was performed using the sliding window technique, employing the Helios algorithm of the Eclipse ® Planning System (version 7.1.59, Varian Medical Systems, Palo Alto, CA). In the planning process, two tangential fields were utilized. The dose constraints were as follows: the planning target volume was to receive 50.0 Gy; no more than 20% of the ipsilateral lung was to receive more than 20 Gy. For left breast cancers, a dose-volume constraint of no more than 20% of the heart to receive more than 30.0 Gy. An example of a typical breast IMRT plan is shown in Figure 3 . Prior to treatment delivery, the IMRT plan for each patient was validated on the Varian linear accelerator using a phantom to confirm the dose delivery and intensity map.
The conventional 3D breast treatment technique consisted of two tangential fields with wedges. The planning was performed using an ADAC ® treatment planning system. The superior, inferior, medial, and lateral borders of both fields were 2 cm beyond the palpable breast tissue. The medial and lateral tangential fields were aligned and adjusted so that only 2-3 cm of lung was included in the tangential portals. Wedges were used in the lateral tangent to achieve uniform dose distribution in the primary breast. The wedge angle ranged from 30 to 60 degrees. A wedge was used in medial tangential field only if there was unacceptable dose homogeneity within the breast. A typical example of field arrangement and isodose plan is shown in Figure 4 .
No patients in the IMRT and the conventional treatment groups had supraclavicular, internal mammary, or axillary fields in their treatment plans, and the dose prescription was 50.0 Gy in 25 fractions given five fractions per week for five weeks. Paired thermoluminescent dosimeters (TLDs, LiF, 3.0 mm × 3.0 mm × 0.9 mm) (Harshaw/Bicron, Solon, Ohio, USA) were placed on each patient's skin just above the balloon catheter for MammoSite ® treatments ( Figure 5 ) and 4 cm inside the treatment borders for IMRT and the conventional treatments. The TLDs were left on the patient during a single fraction of radiation and then measured 24 hours afterwards using the Harshaw model 5500 TLD reader (Thermo Electron Corporation, Santa Fe, New Mexico). For each patient readings from the paired TLDs were averaged and a variance of less than three percent was required in order to be included for analysis. The dose to the skin was calculated as a percentage of the dose prescribed to the primary breast.
Using SPSS statistical package (SPSS, Inc., Chicago, IL), a two tailed t-test was performed to compare the skin doses for patients treated with MammoSite ® technique versus the IMRT and the conventional techniques.
Results
For the patients treated with the MammoSite ® HDR technique the minimum skin to balloon distance ranged from 0.5 to 3.4 cm with a mean of 1.57 cm. The mean dose measured Table I ). These comparisons are also displayed as Box and Whisker Plot in Figure 6 . The Box plot displays the univariate distribution of the metrics. This plot is described in detail in Hoaglin et al. (22) . The top and bottom of the box represent the third and first quartile, respectively; the middle black band indicates the median; the whiskers extend over the range of non-outlying observation.
TLD's on Skin
In order to compare the doses delivered to skin from HDR and EBRT, the linear-quadratic model was used to convert both doses to biologically effective doses (BED) (23). For the patients treated with the MammoSite ® HDR technique, the BED 3 for skin was 34.0 Gy with a standard deviation (SD) of 17.3Gy. In contrast, the BED 3 for skin were 50.6 Gy [SD=6.5Gy] for the patients treated with the IMRT technique and 52.2Gy [SD=5.8Gy] for the patients treated with the conventional technique, respectively. In terms of absolute BED 3 , this represents a 16.6 Gy reduction for the MammoSite ® HDR technique compared to the IMRT technique; and a 18.2 Gy reduction compared to the conventional technique. These reductions are statistically significant (p<0.001; Table II ).
Discussion
The present study demonstrated that for definitive primary breast irradiation following breast-conserving surgery, the use of the MammoSite ® HDR technique reduces the dose to the skin compared to the use of the IMRT or conventional treatment technique. The skin dose exponentially decreases with increasing distance with mammosite brachytherapy and the decreased skin dose in our series is explained by the adequate skin to balloon distance with a mean of 1.57 cm.
Though direct comparison of BED 3 for MammoSite ® with BED 3 for IMRT and conventional is meaningless, because MammoSite ® has an overall treatment time of only five to seven days compared with five weeks for the other schedules. Besides with MammoSite ® only a small volume of skin is treated in comparison to external beam radiation therapy. However, it is worthwhile to see the trend in terms of reduction in biological dose to skin with MammoSite ® compared with external beam radiation therapy.
In the treatments using the MammoSite ® HDR technique, the mean dose to the skin mean dose measured showed a relatively large standard deviation (21% of the prescription dose). The large variation in the skin dose may arise from two sources: large variations in the skin-balloon distance among the patients and TLD placement variations.
Due to the nature of the brachytherapy, the skin dose is not only sensitive to the balloon-skin distance but also to the relative location of the TLDs on the skin surface. The TLD placement uncertainties were calculated for different scenarios -for small (volume 34cc, width 4cm), medium (volume 54cc, width 4.7cm), and large (volume 70cc, width 5.15cm) MammoSite ® balloons. The 1 to 5 mm uncertainity in TLD placement can cause measured dose difference of approximately 7% to 36% for small balloon, 6% to 32% for medium balloon, and 6% to 30% for the large balloon.
Although great care was taken in virtually placing TLD on the skin to be in approximately same location, it is important to note that TLD readings were taken at a single point that may not necessarily be reflective of the entire skin dose, particularly with the MammoSite ® HDR technique because of varying skin to balloon distances at different skin locations.
Conclusion
This study suggests that the MammoSite ® HDR technique may significantly reduce the dose to the skin for breast cancer patients compared to the IMRT and the conventional radiation techniques in patients with adequate skin to balloon distance. This dose reduction may lead to better cosmetic results for patients treated with the MammoSite ® HDR technique than with the IMRT and the conventional radiation techniques.
